Shortcomings in the current treatment of epilepsy

Expert Review of Neurotherapeutics

Volumn 12, Issue 12, 2012, Pages 1419-1427

  Eadie, Mervyn J ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

antiepileptic drugs; cure; epilepsy; prognosis; seizures; therapy; withdrawal

Indexed keywords

CARBAMAZEPINE; ETHOSUXIMIDE; ETIRACETAM; GABAPENTIN; HARKOSERIDE; LAMOTRIGINE; PHENOBARBITAL; PHENYTOIN; POTASSIUM BROMIDE; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

COMORBIDITY; DISEASE CONTROL; DRUG BLOOD LEVEL; DRUG CONCENTRATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EPILEPSY; EPILEPTOGENESIS; FAINTNESS; FEBRILE CONVULSION; FOLLOW UP; GENERAL HOSPITAL; HEAD INJURY; HUMAN; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); MYOCLONUS EPILEPSY; NEUROLOGIST; PATIENT COMPLIANCE; PREGNANCY; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEIZURE; STATISTICAL ANALYSIS; TONIC CLONIC SEIZURE; UNCONSCIOUSNESS; VAGUS NERVE STIMULATION;

ANTICONVULSANTS; EPILEPSY; HUMANS;

EID: 84871081373     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.12.129     Document Type: Review

References (72)

1. Cockerell OC, Johnson AL, Sander JW, Hart YM, Shorvon SD. Remission of epilepsy: results from the National General Practice Study of Epilepsy. Lancet 346(8968), 140-144 (1995).
2. Sander JW. The epidemiology of epilepsy revisited. Curr. Opin. Neurol. 16(2), 165-170 (2003). (Pubitemid 36521202)
3. Sander JW. Some aspects of prognosis in the epilepsies: a review. Epilepsia 34(6), 1007-1016 (1993). (Pubitemid 24004236)
4. Banerjee PN, Hauser WA. Incidence and prevalence. In: Epilepsy: A Comprehensive Textbook (Second edition). Engel JJ, Pedley TA (Eds). Wolters Kluwer/Lippincott Williams & Wilkins, Philadelphia, PA, USA 45-56 (2008).
5. Beghi E, Sander JW. The natural history and prognosis of epilepsy. In: Epilepsy: A Comprehensive Textbook (Second edition). Engel JJ, Pedley TA (Eds). Wolters Kluwer/Lippincott Williams & Wilkins, Philadelphia, PA, USA, 65-70 (2008).
6. Delasiauve LJF. Traite de l' épilepsie. Masson, Paris, France (1854).
7. Reynolds JR. The Diagnosis of Diseases of the Brain, Spinal Cord, Nerves and Their Appendages. J Churchill, London, UK (1855).
8. Gowers WR. Epilepsy And Other Chronic Convulsive Disorders (First edition). J & A Churchill, London, UK (1881).
9. Herpin T. Des Accès Incomplets d'Épilepsie. Balliere, Paris, France (1867).
10. Taylor JE. Selected Writings of John Hughlings Jackson. Staples Press, London, UK (1958).
11. Berg AT. Epilepsies. In: Atlas of the Epilepsies. Paniatopoulos CP (Ed.). Springer, Heidelberg, Germany, 6-10 (2010).
12. Gudmundsson G. Epilepsy in Iceland. Acta Neurol. Scandinav. 43(Suppl. 25), 4-124 (1966).
13. Hart YM, Sander JW, Johnson AL, Shorvon SD. National General Practice Study of Epilepsy: recurrence after a first seizure. Lancet 336(8726), 1271-1274 (1990). (Pubitemid 20382980)
14. Berg AT, Shinnar S. The risk of seizure recurrence following a first unprovoked seizure: a quantitative review. Neurology 41(7), 965-972 (1991).
15. Beghi E, Ciccone A. Recurrence after a first unprovoked seizure. Is it still a controversial issue? First Seizure Trial Group (first). Seizure 2(1), 5-10 (1993).
16. First Seizure Trial Group. Randomized clinical trial on the efficacy of antiepileptic drugs in reducing the risk of relapse after a first unprovoked tonic-clonic seizure. Neurology 43, 478-483 (1993).
17. Musicco M, Beghi E, Solari A, Viani F. Treatment of first tonic-clonic seizure does not improve the prognosis of epilepsy. First Seizure Trial Group (FIRST Group). Neurology 49(4), 991-998 (1997). (Pubitemid 27456076)
18. MacDonald B. The prognosis of epilepsy. Seizure 10(5), 347-358 (2001). (Pubitemid 32755358)
19. Locock C. Discussion following Dr Sieveking 'Analysis of fifty-two cases of epilepsy observed by the author'. Med. Times Gaz. i, 524-526 (1857).
20. Locock C. Discussion of paper by E.H.Sieveking. Analysis of fifty-two cases of epilepsy observed by the author. Lancet 59, 527 (1857).
21. Wilks S. Bromide and iodide of potassium in epilepsy. Med. Times Gaz. ii, 635-636 (1861).
22. Shinnar S, Berg AT. Does antiepileptic drug therapy prevent the development of 'chronic' epilepsy? Epilepsia 37(8), 701-708 (1996). (Pubitemid 26276936)
23. Prenx PM, Duret-Cabanac M. Epidemiology and aetiology of epilepsy in sub-Saharan Africa. Lancet Neurol. 4, 21-31 (2005).
24. Hauser AW, Lee JW. Do seizures beget seizures? Prog. Brain Res. 135, 215-219 (2002).
25. Adie WJ. Pyknolepsy: a form of epilepsy occurring in children, with a good prognosis. Brain 47, 96-101 (1924).
26. Loiseau P, Pestre M, Dartigues JF, Commenges D, Barberger-Gateau C, Cohada S. Long-term prognosis in two forms of childhood epilepsy: typical absences and epilepsy with Rolandic (centrotemporal) EEG foci. Ann. Neurol. 13, 642-648 (1993).
27. Annegers JF, Hauser WA, Elveback LR, Kurland LT. The risk of epilepsy following febrile convulsions. Neurology 29(3), 297-303 (1979). (Pubitemid 9111008)
28. Camfield CS, Camfield PR. Juvenile myoclonic epilepsy 25 years after seizure onset: a population-based study. Neurology 73(13), 1041-1045 (2009).
29. Löscher W, Schmidt D. Modern antiepileptic drug development has failed to deliver: ways out of the current dilemma. Epilepsia 52(4), 657-678 (2011).
30. Costa J, Fareleira F, Ascenção R, Borges M, Sampaio C, Vaz-Carneiro A. Clinical comparability of the new antiepileptic drugs in refractory partial epilepsy: a systematic review and meta-analysis. Epilepsia 52(7), 1280-1291 (2011).
31. Beghi E. Efficacy and tolerability of the new antiepileptic drugs: comparison of two recent guidelines. Lancet Neurol. 3(10), 618-621 (2004). (Pubitemid 39221928)
32. Noachtar S, Andermann E, Meyvisch P, Andermann F, Gough WB, Schiemann-Delgado J; N166 Levetiracetam Study Group. Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures. Neurology 70(8), 607-616 (2008). (Pubitemid 351294638)
33. Fattore C, Boniver C, Capovilla G et al. A multicenter, randomized, placebo-controlled trial of levetiracetam in children and adolescents with newly diagnosed absence epilepsy. Epilepsia 52(4), 802-809 (2011).
34. Reynolds EH. Do anticonvulsants alter the natural course of epilepsy? Treatment should be started as early as possible. BMJ 310(6973), 176-177 (1995).
35. MacDonald BK, Johnson AL, Goodridge DM, Cockerell OC, Sander JW, Shorvon SD. Factors predicting prognosis of epilepsy after presentation with seizures. Ann. Neurol. 48(6), 833-841 (2000).
36. Camfield C, Camfield P, Gordon K, Dooley J. Does the number of seizures before treatment influence ease of control or remission of childhood epilepsy? Not if the number is 10 or less. Neurology 46(1), 41-44 (1996). (Pubitemid 26156099)
37. Brodie MJ. Diagnosing and predicting refractory epilepsy. Acta Neurol. Scand., Suppl.c 181, 36-39 (2005).
38. Deckers CL, Genton P, Sills GJ, Schmidt D. Current limitations of antiepileptic drug therapy: a conference review. Epilepsy Res. 53(1-2), 1-17 (2003). (Pubitemid 36170166)
39. Sisodiya SM. Mechanisms of antiepileptic drug resistance. Curr. Opin. Neurol. 16(2), 197-201 (2003). (Pubitemid 36521207)
40. Siddiqui A, Kerb R, Weale ME et al. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N. Engl. J. Med. 348(15), 1442-1448 (2003). (Pubitemid 36407173)
41. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N. Engl. J. Med. 342(5), 314-319 (2000). (Pubitemid 30075244)
42. French JA. Refractory epilepsy: clinical overview. Epilepsia 48(Suppl. 1), 3-7 (2007). (Pubitemid 46280512)
43. Sillanpää M, Schmidt D. Is incident drug-resistance of childhood-onset epilepsy reversible? A long-term follow-up study. Brain 135(Pt 7), 2256-2262 (2012).
44. Macdonald RL. Cellular action of antiepileptic drugs. In: Antiepileptic Drugs. Pharmacology and Therapeutics. Eadie MJ, Vajda FJE (Eds). Springer, Berlin, Germany, 123-150 (1999).
45. Brodie MJ, Sills GJ. Combining antiepileptic drugs-rational polytherapy? Seizure 20(5), 369-375 (2011).
46. Jackson JH. Remarks on the diagnosis and treatment of diseases of the brain. Br. Med. J. 2(1437), 59-63 (1888).
47. Jackson JH. A study of convulsions. Transact. St Andrews Med. Graduates Assoc. 3, 162-204 (1870).
48. Jackson JH. On the anatomical and physiological localisation of movements in the brain. Lancet 101, 232-235 (1873).
49. Berg AT, Shinnar S, Levy SR, Testa FM, Smith-Rapaport S, Beckerman B. How well can epilepsy syndromes be identified at diagnosis? A reassessment 2 years after initial diagnosis. Epilepsia 41(10), 1269-1275 (2000).
50. Eadie MJ. Plasma antiepileptic drug monitoring in a neurological practice: a 25-year experience. Ther. Drug Monit. 16(5), 458-468 (1994). (Pubitemid 24296736)
51. Schmidt D, Einicke I, Haenel F. The influence of seizure type on the efficacy of plasma concentrations of phenytoin, phenobarbital, and carbamazepine. Arch. Neurol. 43(3), 263-265 (1986). (Pubitemid 16117840)
52. Eadie MJ, Heazlewood R, Tyrer JH. How worthwhile is plasma primidone measurement? Clin. Exp. Neurol. 18, 123-131 (1981).
53. McKauge L, Tyrer JH, Eadie MJ. Factors influencing simultaneous concentrations of carbamazepine and its epoxide in plasma. Ther. Drug Monit. 3(1), 63-70 (1981). (Pubitemid 11096966)
54. Patsalos PN, Berry DJ, Bourgeois BF et al. Antiepileptic drugs-best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 49(7), 1239-1276 (2008). (Pubitemid 351991390)
55. Levy RH, Yerby MS. Effects of pregnancy on antiepileptic drug utilization. Epilepsia 26(Suppl. 1), S52-S57 (1985). (Pubitemid 15013910)
56. Lander CM, Eadie MJ. Plasma antiepileptic drug concentrations during pregnancy. Epilepsia 32(2), 257-266 (1991).
57. Knight AH, Rhind EG. Epilepsy and pregnancy: a study of 153 pregnancies in 59 patients. Epilepsia 16(1), 99-110 (1975).
58. Schmidt D. The effect of pregnancy on the natural history of epilepsy: review of the literature. In: Epilepsy, Pregnancy and the Child. Janz D, Bossi L, Dam M, Helge H, Richens A, Schmidt D (Eds). Raven Press, NY, USA, 3-14 (1982).
59. Meadow SR. Congenital abnormalities and anticonvulsant drugs. Proc. R. Soc. Med. 63(1), 48-49 (1970).
60. Vajda FJ, Eadie MJ. Maternal valproate dosage and foetal malformations. Acta Neurol. Scand. 112(3), 137-143 (2005). (Pubitemid 41153043)
61. Morrow J, Russell A, Guthrie E et al. Malformation risk of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J. Neurol. Neurosurg. Psychiat. 77, 193-198 (2006). (Pubitemid 43220841)
62. Reimers A, Brodtkorb E. Second-generation antiepileptic drugs and pregnancy: a guide for clinicians. Expert Rev. Neurother. 12(6), 707-717 (2012).
63. Meador KJ, Baker GA, Browning N et al. Cognitive function at 3 years after fetal exposure to antiepileptic drugs. N. Engl. J. Med. 360, 1587-1605 (2009).
64. Meador KJ, Baker GA, Browning N et al.; NEAD Study Group. Effects of fetal antiepileptic drug exposure: outcomes at age 4.5 years. Neurology 78(16), 1207-1214 (2012).
65. Spencer S, Huh L. Outcomes of epilepsy surgery in adults and children. Lancet Neurol. 7(6), 525-537 (2008). (Pubitemid 351657493)
66. Ben-Menachem E. Vagus-nerve stimulation for the treatment of epilepsy. Lancet Neurol. 1(8), 477-482 (2002). (Pubitemid 37159138)
67. Neal EG, Chaffe H, Schwartz RH et al. The ketogenic diet for the treatment of childhood epilepsy: a randomised controlled trial. Lancet Neurol. 7(6), 500-506 (2008).
68. Mohanraj R, Brodie MJ. Diagnosing refractory epilepsy: response to sequential treatment schedules. Eur. J. Neurol. 13(3), 277-282 (2006).
69. Shorvon S. The treatment of chronic epilepsy: a review of recent studies of clinical efficacy and side effects. Curr. Opin. Neurol. 20(2), 159-163 (2007). (Pubitemid 46411500)
70. Shinnar S, Pellock JM. Update on the epidemiology and prognosis of pediatric epilepsy. J. Child Neurol. 17(Suppl. 1), S4-S17 (2002). (Pubitemid 34460806)
71. Specchio LM, Tramacere L, La Neve A, Beghi E. Discontinuing antiepileptic drugs in patients who are seizure free on monotherapy. J. Neurol. Neurosurg. Psychiatr. 72(1), 22-25 (2002). (Pubitemid 34073090)
72. Oller-Daurella L, Pamies R, Oller L. Reduction or discontinuance of antiepileptic drugs in patients seizure-free for more than 5 years. In: Epileptology. Janz D (Ed.). Thieme, Stuttgart, Germany 218-227 (1976).